- Home
- RGC vs LCTX Comparison
RGC vs LCTX Comparison
Compare RGC & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- LCTX
- Stock Information
- Founded
- RGC 2014
- LCTX 1990
- Country
- RGC Hong Kong
- LCTX United States
- Employees
- RGC N/A
- LCTX N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RGC Health Care
- LCTX Health Care
- Exchange
- RGC Nasdaq
- LCTX Nasdaq
- Market Cap
- RGC 105.3M
- LCTX 110.2M
- IPO Year
- RGC 2021
- LCTX N/A
- Fundamental
- Price
- RGC $4.86
- LCTX $0.55
- Analyst Decision
- RGC
- LCTX Strong Buy
- Analyst Count
- RGC 0
- LCTX 5
- Target Price
- RGC N/A
- LCTX $4.80
- AVG Volume (30 Days)
- RGC 8.8K
- LCTX 2.9M
- Earning Date
- RGC 10-25-2024
- LCTX 03-06-2025
- Dividend Yield
- RGC N/A
- LCTX N/A
- EPS Growth
- RGC N/A
- LCTX N/A
- EPS
- RGC N/A
- LCTX N/A
- Revenue
- RGC N/A
- LCTX $8,719,000.00
- Revenue This Year
- RGC N/A
- LCTX N/A
- Revenue Next Year
- RGC N/A
- LCTX $41.15
- P/E Ratio
- RGC N/A
- LCTX N/A
- Revenue Growth
- RGC N/A
- LCTX N/A
- 52 Week Low
- RGC $3.03
- LCTX $0.48
- 52 Week High
- RGC $32.44
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- RGC 44.96
- LCTX 47.26
- Support Level
- RGC $4.75
- LCTX $0.51
- Resistance Level
- RGC $5.21
- LCTX $0.60
- Average True Range (ATR)
- RGC 0.30
- LCTX 0.04
- MACD
- RGC 0.04
- LCTX 0.01
- Stochastic Oscillator
- RGC 23.87
- LCTX 53.85
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.